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Abstract: 
 
Despite growing popularity in dietary supplements, many medicinal mushrooms have not been 
evaluated for their safe human consumption using modern techniques. The multifaceted 
approach described here relies on five key principles to evaluate the safety of non-
culinary fungi for human use: (1) identification by sequencing the nuclear ribosomal internal 
transcribed spacer (ITS) region (commonly referred to as ITS barcoding), (2) screening an 
extract of each fungal raw material against a database of known fungal metabolites, (3) 
comparison of these extracts to those prepared from grocery store-bought culinary mushrooms 
using UHPLCPDA-ELS-HRMS, (4) review of the toxicological and chemical literature for each 
fungus, and (5) evaluation of data establishing presence in-market. This weight-of-evidence 
approach was used to evaluate seven fungal raw materials and determine safe human use for 
each. Such an approach may provide an effective alternative to conventional toxicological 
animal studies (or more efficiently identifies when studies are necessary) for the safety 
assessment of fungal dietary ingredients. 
 
Keywords: Human safety | Dietary ingredient | Supplements | Barcoding | Fungi | UHPLC-
HRMS 
 
Article: 
 
***Note: Full text of article below 
lable at ScienceDirect
Food and Chemical Toxicology 103 (2017) 133e147Contents lists avaiFood and Chemical Toxicology
journal homepage: www.elsevier .com/locate/ foodchemtoxSafety assessment of mushrooms in dietary supplements by
combining analytical data with in silico toxicology evaluation
Karen M. VanderMolen a, b, *, Jason G. Little a, c, Vincent P. Sica d, e, Tamam El-Elimat d, f,
Huzefa A. Raja d, Nicholas H. Oberlies d, Timothy R. Baker e, Catherine Mahony g
a Product Safety and Regulatory Affairs, New Chapter, Inc., 90 Technology Dr, Brattleboro, VT 05301, United States
b Central Product Safety, The Procter and Gamble Company, Winton Hill Business Center, 6100 Center Hill Ave, Cincinnati, OH 45232, United States
c Personal Health Care, The Procter and Gamble Company, Mason Business Center, 8700 Mason-Montogomery Rd, Mason, OH 45040, United States
d Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro NC 27402, United States
e Research and Development, Corporate Functions Analytical, The Procter & Gamble Company, Mason Business Center, 8700 Mason-Montogomery Rd,
Mason, OH 45040, United States
f Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan
g Central Product Safety, Procter and Gamble Company Technical Centres Ltd, Egham, Surrey TW20 9NW, United Kingdoma r t i c l e i n f o
Article history:
Received 16 November 2016
Received in revised form
30 January 2017
Accepted 2 March 2017
Available online 4 March 2017
Keywords:
Human safety
Dietary ingredient
Supplements
Barcoding
Fungi
UHPLC-HRMS* Corresponding author. Central Product Safety, Th
pany, Winton Hill Business Center, 6100 Center Hil
United States.
E-mail addresses: vandermolen.k@pg.com (K.M.
com (J.G. Little), sica.vp@pg.com (V.P. Sica), telima
haraja@uncg.edu (H.A. Raja), nicholas_oberlies@unc
tr@pg.com (T.R. Baker), mahony.c@pg.com (C. Mahon
http://dx.doi.org/10.1016/j.fct.2017.03.005
0278-6915/© 2017 The Authors. Published by Elseviera b s t r a c t
Despite growing popularity in dietary supplements, many medicinal mushrooms have not been evalu-
ated for their safe human consumption using modern techniques. The multifaceted approach described
here relies on five key principles to evaluate the safety of non-culinary fungi for human use: (1) iden-
tification by sequencing the nuclear ribosomal internal transcribed spacer (ITS) region (commonly
referred to as ITS barcoding), (2) screening an extract of each fungal raw material against a database of
known fungal metabolites, (3) comparison of these extracts to those prepared from grocery store-bought
culinary mushrooms using UHPLCPDA-ELS-HRMS, (4) review of the toxicological and chemical literature
for each fungus, and (5) evaluation of data establishing presence in-market. This weight-of-evidence
approach was used to evaluate seven fungal raw materials and determine safe human use for each.
Such an approach may provide an effective alternative to conventional toxicological animal studies (or
more efficiently identifies when studies are necessary) for the safety assessment of fungal dietary
ingredients.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As a source of diverse secondary metabolites, fungi have
enjoyed a long history of use in both culinary and medicinal ap-
plications (Das et al., 2010; Kalaivani et al., 2010; Paterson, 2006;
Rios, 2011; Xu, 2012). While some of the chemically interesting
and/or biologically active constituents are shared across all fungi
(e.g, b-glucans (Dalonso et al., 2015)), others are exclusive to spe-
cific species or genera (Patakova, 2013; Xu, 2012), and somee Procter and Gamble Com-
l Ave, Cincinnati, OH 45232,
VanderMolen), little.j.6@pg.
t@just.edu.jo (T. El-Elimat),
g.edu (N.H. Oberlies), baker.
y).
Ltd. This is an open access article uconstituents may only be produced under distinct growing condi-
tions (Wang et al., 2014). In general, many medicinal mushrooms
have not been evaluated for their safe human use using modern
analytical approaches. While history of use data should be carefully
considered, and can provide a foundation for establishing safe use,
some toxicological endpoints may be more opaque. Obtaining
safety data for developmental and reproductive toxicity (DART),
genotoxicity, and chronic endpoints can prove particularly difficult.
Complicating the evaluation of such fungi, modern cultivation
practices and preparations are rarely consistent with traditional
medicinal uses. While fruiting bodies are most often the portion of
the organism used in traditional Chinese medicine (TCM) (Bensky
et al., 2004), commercial raw materials typically consist of the
fungi's mycelium, which grows more quickly and is therefore less
expensive to produce. In addition, the growing conditions can
impact the secondary metabolite profile of fungi (Bills et al., 2008;
Bode et al., 2002; Fiedurek et al., 1996; Miao et al., 2006; Mohantynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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profoundly the ability of investigators to bridge data generated
from different raw materials or different suppliers, even of the
same species.
Given these challenges, a multifaceted approach was developed
to establish safe human use of fungi as dietary ingredients. The
approach described here relies on five key principles to evaluate the
safety of non-culinary fungi for human consumption. (1) A critical
starting point in the safety review of fungal raw material is
confirmation of identity. There exist numerous challenges associ-
ated with macro- and microscopic identification of fungi, not least
of which is the subjectivity of the analysis. Morphological differ-
ences due to sexual and asexual states of the same species confuses
the conventional taxonomical nomenclature, causing multiple
names to be assigned to genetically identical species of fungi
(termed ‘pleomorphy’) (Sugiyama, 1987). With advances in the
speed and cost of genetic analysis, the issue of fungal identity can
now be more adequately addressed by DNA identification (Raja
et al., 2017). All fungal raw materials evaluated in this study
were, as a first step, identified by sequencing the nuclear ribosomal
internal transcribed spacer (ITS) region (commonly referred to as
ITS barcoding) (Raja et al., 2017; Schoch et al., 2012). (2) The next
step was to screen an extract of each fungal raw material against a
database of known fungal metabolites, as a way to quickly identify
known toxins. (3) This was followed by a comparison of these ex-
tracts to those prepared from store-bought culinary mushrooms.
Mushrooms that are widely consumed and well established as food
in broad and diverse populations can provide a relatively innocuous
baselinewith which to compare common constituents, and exclude
shared components that should not raise a safety concern. (4)
Available toxicological and chemical literature for each fungus was
reviewed for available safety data. (5) Marketplace data were used
to establish presence in the market.
This weight-of-evidence approach was used to evaluate seven
fungal raw materials and determine safe human use for each; two
of the raw materials are used as in-detail examples, while the re-
sults of the remaining raw materials are summarized. We believe
that this comprehensive approach will provide an effective alter-
native to conventional toxicological animal studies (or identify
when studies are necessary) for the safety assessment of fungal
dietary ingredients.
2. Methods
2.1. Approach to safety evaluation
The assessment of each fungal raw material's safe use as a di-
etary ingredient was performed using a weight-of-evidence
approach, with the following criteria: (1) DNA identification, (2)
screening fungal rawmaterial extracts against a database of known
fungal metabolites (dereplication), (3) similarity to grocery store
(culinary) mushrooms as determined by UHPLC-PDA-ELS-HRMS
(ultrahigheperformance liquid chromatographyephotodiode
arrayeevaporative light scatteringehigh resolution mass spec-
trometry), (4) expert opinion and literature review, and (5)
marketplace data. Detailed descriptions of each of these criteria are
outlined below. Based on the strength and totality of evidence,
conclusions were drawn as to the supportable use of the raw ma-
terial as a dietary ingredient. A decision tree outlines the general
approach used to evaluate the available evidence (Fig. 1).
2.2. Materials
Seven fungal raw materials were purchased from a commercial
supplier, and were identified by the supplier as Chaga (Inonotusobliquus), Wild-Crafted Chaga (Inonotus obliquus), Turkey Tail
(Trametes versicolor), Shiitake (Lentinula edodes), Maitake (Grifola
frondosa), Reishi (Ganoderma lucidum) fruiting bodies and myce-
lium, and Cordyceps (Cordyceps sinensis). The Chaga, Turkey Tail,
Shiitake, Maitake, and Cordyceps were grown on brown rice and
consisted primarily of mycelium. The Wild-Crafted Chaga was
harvested from its natural habitat by the supplier. The Reishi was
composed 80:20 of two subcomponents: 80% was grown on brown
rice and consisted primarily of mycelium, and 20% was fruiting
bodies grown on sawdust (no sawdust is incorporated into the raw
material). These subcomponents were obtained as separate mate-
rials, allowing us to analyze them individually. The supplier also
provided a sample of the brown rice that was used to grow the
fungi. A selection of dried culinary mushrooms (including Shiitake,
Black Trumpet, Chanterelle, Crimini, and Porcini) were purchased
from a local grocery store to use during the comparison of the
fungal raw materials to store-bought mushrooms.
2.3. DNA identification of fungi samples
Methods for the identification of these fungal samples
(including DNA extraction, PCR amplification, and Sanger
sequencing of dry powdered mycelium and/or fruiting body) have
been described in detail previously (Raja et al., 2017).
2.4. Extractions
All samples were extracted by adding 60 mL of 1:1 methanol-
chloroform (MeOHeCHCl3) to a 15 g aliquot of each powdered
material and shaking overnight (~16 h) at 100 rpm at RT. The
sample was filtered using vacuum, and the remaining residues
werewashed with 10 mL of 1:1 MeOHeCHCl3. To the filtrate, 90 mL
of CHCl3 and 150mL of H2Owere added; themixturewas stirred for
1 h and then transferred into a separatory funnel. The bottom
(organic) and upper (aqueous) layers were drawn off and evapo-
rated to dryness. The dried organic extract was re-constituted in
50 mL of 1:1 MeOHeCH3CN and 50 mL of hexanes. The biphasic
solution was stirred for 0.5 h and then transferred to a separatory
funnel. The MeOHeCH3CN layer was drawn off and evaporated to
dryness under vacuum (see Fig. 2).
The extraction scheme was developed based on previous
experience of the authors and consideration of the relevant liter-
ature, especially an exhaustive study by researchers with the Na-
tional Cancer Institute (McCloud, 2010). Essentially, the polarity of
1:1 MeOHeCHCl3 is such that most 'organic' soluble molecules are
extracted efficiently.
2.5. UHPLCePDAeELSeHRMS analysis
Analysis was performed using an ultrahigheperformance liquid
chromatographyephotodiode arrayeevaporative light scatter-
ingehigh resolution mass spectrometry (UHPLCePDA-
eELSeHRMS) method. A splitter was incorporated postePDA to
allow for simultaneous analysis by both the ELS detector (ELSD) and
mass spectrometer. HRMS was performed on a Thermo LTQ Orbi-
trap XL mass spectrometer (ThermoFisher, San Jose, CA) equipped
with an electrospray ionization (ESI) source. The source conditions
were set to aquire (m/z 100e2000) positive-ionization modewith a
capillary temperature of 300 C, a source voltage of 4.0 kV, a
capillary voltage of 20 V, and the tube lens set to 100 V. Der-
eplicated compounds were confirmed by performing tandem mass
spectrometry (MS/MS) with a collision induced dissociation set to
30%. UHPLC was carried out on a Waters Acquity system [using a
BEH C18 (2.1  50 mm, 1.7 mm) column (Waters Corp., Massachu-
setts, USA) equilibrated at 40 C]. Negative-ionization mode was
Fig. 1. Decision tree for evaluation of fungal raw materials.
Fig. 2. Extraction scheme for fungal samples.
K.M. VanderMolen et al. / Food and Chemical Toxicology 103 (2017) 133e147 135previously shown to not provide additional information (El-Elimat
et al., 2013), and thus was not used. The mobile phase consisted of
CH3CNeH2O (both acidified with 0.1% formic acid), which started at
15% CH3CN for 1 min, increased linearly to 100% CH3CN over 7 min,
held for 1.5 min, and then returned to the starting conditionswithin 0.5 min. Analyses were performed using Fisher optima LC/
MS grade CH3CN and H2O. An Acquity UPLC PDA detector was used
to acquire UV/VIS spectra, which were collected from 200 to
500 nmwith 4 nm resolution. An Acquity UPLC ELSDwas used with
a gas pressure of 40 psi, a nebulizer temperature of 40 C, and a drift
K.M. VanderMolen et al. / Food and Chemical Toxicology 103 (2017) 133e147136tube temperature of 60 C. The MeOHeCH3CN extracts and myco-
toxin standards were prepared in 1:1 MeOHedioxane to a con-
centration of 2 mg/mL and 1 mg/mL, respectively.
While developing the method, it became clear that it would be
necessary to ensure that both the ELSD and the mass spectrometer
were reporting the information simultaneously in order to corre-
late the accurate masses (from the MS) with their corresponding
contribution to the composition of the extract (from the ESLD).
Since the flow from the UHPLC was split post-PDA to the two de-
tectors, bufotenine was used as a standard to determine the lag (if
any) between the signal from the ELSD to the signal of the mass
spectrometer. The time difference between the two detectors was
determined to be 0.11 min, allowing for accurate alignment of the
data during analyses.
2.6. Dereplication
A database consisting of over 300 fungal secondary metabolites
was previously assembled containing the retention times, UV data,
HRMS data and MS/MS fragmentation patterns of each compound
(El-Elimat et al., 2013). This database was comprised of compounds
that were isolated from fungi largely due to their cytotoxic prop-
erties. In addition to those compounds, six known mycotoxins,
specifically from mushrooms, were added to the database,
including: ibotenic acid (1), muscimol (2), 2-amino-hexynoic acid
(3), muscarine chloride (4), bufotenine (5), and phalloidin (6)
(Fig. 3). Each fungal sample was prepared at 2 mg/mL and analyzed
via the UHPLC-PDA-ELS-HRMS method described above. The raw
data files were uploaded into ACD MS Manager (v 2015.2.5) with
the add-in software Intellixtract (Advanced Chemistry Develop-
ment, Inc., Toronto, Canada). Intellixtract rapidly deconvoluted the
complex UHPLC-HRMS chromatograms and cross-referenced the
pseudomolecular ion peaks with the database. Any matches in
retention time and HRMSwere then manually analyzed confirming
that the retention time, UV data, HRMS and MS/MS matched the
standard.
2.7. Comparison to culinary mushrooms
Using the UHPLCePDAeELSeHRMS methodology described in
section 2.5, for each sample, all the peaks that contributed >0.33%
ELSD of the total signal were examined. Each constituent m/z was
checked against corresponding peaks in the store-bought culinaryFig. 3. The six known mycotoxins from mushrooms that were added to the fungal second
muscarine chloride (4), bufotenine (5), and phalloidin (6).mushroom (Porcini, Crimini, Black Trumpet, Chanterelle, and Shii-
take) and brown rice extracts. A “match” was assigned if the ac-
curate mass (±5 ppm), retention time, and contribution to the ELSD
signal were consistent with at least one of the culinary extracts.
After matches for summed mass spectral signal corresponding
to each ELSD peak were determined, the peak was assigned a
percent similarity based on the quantity of matched and un-
matched significant ions in each spectrum. Because of the
compound-to-compound variability in ionization/volatilization
efficiency inherent to electrospray mass spectrometry, these
percent similarities were assigned conservatively, with the esti-
mates leaning towards “different” than culinary mushrooms. The
percent similarity of each peak was then multiplied by the area of
its corresponding ELSD signal. Thus, a peak considered to be 10%
different (i.e.10% of the significant peaks could not be matched to
either the culinarymushrooms or organic brown rice) with an ELSD
Area of 33.0% would result in a 3.3% estimation of the mass of the
mushroom extract being designated as different from the store-
bought mushrooms. This process was then repeated for each
ELSD peak, and the results were summed to provide a total %-dif-
ference for each mushroom. This %-difference was then used to
estimate themass of “different”mushroommetabolites expected in
the proposed doses. While all compounds do not ionize to the same
extent, enough ions were analyzed that the net differences should,
in total, balance to statistically represent a reasonable estimation.
Given this, we believe the combination of MS and ELSD data pro-
vided a pragmatic approach to examining the samples in a repro-
ducible and thorough manner.
2.8. Literature review
A thorough review of the currently available toxicological and
chemical literature for each fungus was performed. Traditional
preparations and historical use, such as culinary or medicinal, were
considered. As this paper is not intended to be a systematic review
of the available literature, structured search methodology and in-
clusion and exclusion criteria were not used. The quality of studies
obtained was evaluated on a case-by-case basis.
2.9. In-market data
The Dietary Supplements Labels Database (DSLD), maintained
by the National Institutes of Health (NIH), was used to evaluateary metabolite database: ibotenic acid (1), muscimol (2), 2-amino-hexynoic acid (3),
K.M. VanderMolen et al. / Food and Chemical Toxicology 103 (2017) 133e147 137market presence in the United States. The common names and
Latin binomials of each rawmaterial were used as search terms. The
number of brands, number of products, median, and maximum
doses of each raw material were recorded.
3. Results
Each fungal raw material went through the hazard assessment
process outlined above, using (1) DNA identification, (2) der-
eplication against known fungal metabolites, (3) comparison to
store-bought culinary mushrooms, (4) review of the available
literature, and (5) consideration of marketplace data. Due to space
considerations, the Chaga and Reishi samples are used as examples
for in-depth explanation of the assessment process. Results are
summarized for the remaining fungal raw materials.
3.1. DNA identification of fungi samples
The store-bought Shiitake and Crimini mushrooms were
confirmed by analysis of the ITS region to be Lentinula edodes and
Agaricus bisporus, respectively. The store-bought Porcini was
confirmed to be a Boletus spp, although the ITS region did not have
>80% similarity with the Boletus edulis species. Likewise, the Black
Trumpet was confirmed to be a Craterellus spp, although the ITS
region did not have >80% similarity with the Craterellus comuco-
pioides species. The analysis of the store-bought Chantarelle was
unsuccessful. While a PCR product was obtained, it was not possible
to acquire sufficiently high quality ITS data from the sequencing. A
second sample from the same batch was processed in an identical
fashionwith the same results. These results are likely due to the age
and/or processing of the material, resulting in degradation of the
DNA.
The fungal raw materials (Chaga, Wild-Crafted Chaga, Turkey
Tail, Shiitake, Maitake, Reishi, and Cordyceps) were also analyzed to
confirm identity. The Chaga, Turkey Tail, Shiitake, and Maitake
materials were confirmed to be Inonotus obliquus, Coriolus versi-
color, Lentinula edodes, and Grifola frondosa, respectively. The Reishi
mycelium and fruiting body raw materials shared identical ITS se-
quences; the results from the BLAST search shared >99% sequence
similarity with Ganoderma lucidum. However, the ITS resultsTable 1
List of fungi samples profiled in this study.
Binomial name Common name ITS barcoding ID
Trametes versicolor
(Coriolus versicolor)
Turkey Tail Trametes versicolor (Coriolus
versicolor)
Inonotus obliquus Chaga Inonotus obliquus
Inonotus obliquus Chaga (Sclerotia) Cladosporium sp.
Grifola frondosa Maitake Grifola frondosa
Lentinula edodes Shiitake Lentinula edodes
Wolfiporia cocos (Poria cocos) Poria Wolfiporia cocos (Poria cocos)
Agaricus bisporus Crimini Agaricus bisporus
Lentinula edodes Shiitake Lentinula edodes
Ganoderma ludicum Reishi Ganoderma sichuanense
Ganoderma ludicum Reishi Ganoderma sichuanense
Ganoderma ludicum Reishi Ganoderma sichuanense
Boletus edulis Porcini Boletus shiyong
Craterellus comucopioides Black Trumpet Craterellus comucopioides
Cantharellus cibarius Chanterelle No sequence obtained
Ophiocordyceps sinensis
(Cordyceps sinensis)
Cordyceps Tolypocladium inflatum
a ITS sequences of these fungi were deposited in GenBank in a previous study (Raja e
b To be considered the same species, the ITS should have a80% coverage and97% sim
based on 4.6% variable bases. Although this value is >3% we believe that this may be due t
3.33%with a standard deviation of 5.62 (Nilsson et al., 2008). In addition, the extreme leng
2008).suggested that the sample may be more closely related to the
Chinese variety of G. lucidum, which has been recently given a new
name: G. sichuanense. ITS sequence comparison of the Cordyceps
rawmaterial indicated that the fungus was not a Cordyceps species,
but was instead Tolypocladium inflatum. The ITS sequences of Cor-
dyceps sinensis (now Ophiocordyceps sinensis) were downloaded
from GenBank and compared with those of Tolypocladium inflatum.
Based on these results it was evident that the ITS sequences ob-
tained from the “Cordyceps” raw material were more similar to
those of Tolypocladium inflatum compared to Ophiocordyceps
sinensis. A Randomized Axelerated Maximum Likelihood (RAxML)
analysis also showed that ITS sequences from the “Cordyceps” raw
material grouped with Tolypocladium inflatum, but not with se-
quences from Ophiocordyceps sinensis. The Wild-Crafted Chaga
sample ITS comparison shared 99% similarity with Cladosporium
spp., not Inonotus obliquus. Because the “Cordyceps” and “Wild-
Crafted Chaga” raw materials were not the correct species, further
assessment of these fungi was not pursued; however, these results
emphasize the necessity of positive DNA identification when
assessing a fungal raw material for use in a dietary supplement.
Safety assessment continued for the identity-confirmed Chaga,
Turkey Tail, Shiitake, Maitake, and Reishi raw materials.
Results of the ITS barcoding are summarized in Table 1, which
has been adapted from previously published results (Raja et al.,
2017).3.2. Dereplication
The six remaining fungal raw material extracts (Reishi myce-
lium, Reishi fruiting body, Maitake, Shiitake, Turkey Tail, and Chaga)
were then subjected to a targeted UHPLC-PDA-HRMS/MS protocol
that screened for the presence of cytotoxins and mycotoxins from a
database of over 300 fungal secondary metabolites (El-Elimat et al.,
2013). All of the fungal raw material extracts yielded matches for
fungal metabolites from this database based on retention time, UV
data, HRMS data, and MS/MS data (Table 2). The metabolite
ergosterol peroxide was detected in each extract, but was also
detected in the five store-bought culinary mushroom extracts
(Porcini, Crimini, Blank Trumpet, Chanterelle, and Shiitake). Pyr-
enocine A (Sato et al., 1979, 1981) and pughiinin AGenBank accessionsa GenBank query
coverageb
GenBank percent
similarity
Variable
bases (%)
KT693226, KT693227 100% 100% 1.7%
KT693232, KT693233 100% 99% 1.4%
KT693272, KT693273 98% 99% 0.2%
KT693234, KT693235 98% 99% 0%
KT693236, KT693237 100% 99% 2.9%
KT693238, KT693239 92% 93-95% 4.6%
KT693240, KT693241 98% 99% 0.7%
KT693242, KT693243 98% 99-100% 2.9%
KT693248, KT693249 89% 99% 1.2%
KT693250, KT693251 89% 99% 1.2%
KT693252, KT693253 89% 99% 1.2%
KT693260, KT693261 80% 97-100% 0.8%
KT693262, KT693263 80% 97-100% 0%
N/A N/A e e
KT693266, KT693267 98% 99% 0.2%
t al., 2017).
ilarity. ForWolfiporia cocos,we have assigned an accurate name on the product label
o mushroom forming species having a higher weighted intraspecific ITS variability of
th ofW. cocos ITS is due to insertions in the ITS1 and ITS2 regions (Lindner and Banik,
Table 2
Metabolites dereplicated in fungal raw materials.
Fungal sample Dereplicated metabolites
All
HO
H
H
O
O
Ergosterol peroxide
Turkey Tail None
Chaga None
Reishi None
Reishi Fruiting Body None
Maitake None
Shiitake
O
O
O
O
Pyrenocine A (<0.10% ELSD signal) O OH
OH
Pughiinin A (<0.10% ELSD signal)
K.M. VanderMolen et al. / Food and Chemical Toxicology 103 (2017) 133e147138(Pittayakhajonwut et al., 2002) were detected in the Shiitake
extract with the signal from the ELSD constituting <0.10% of the
total ELSD signal.
3.3. Comparison to culinary mushrooms
An untargeted analysis of the six fungal raw material extracts
(Reishi mycelium, Reishi fruiting body, Maitake, Shiitake, Turkey
Tail, and Chaga) was performed by comparing the UHPLC-PDA-ELS-
HRMS data for the eight extracts to the five store-bought mush-
rooms extracts (Porcini, Crimini, Black Trumpet, Chanterelle, and
Shiitake) and the organic brown rice extract. For each of the eight
fungal raw material extracts, the areas for each peak of the ELSD
chromatograms were calculated. Any peak area totaling over 0.33%
of the overall signal was considered for the analysis. The HRMS data
was examined for each considered peak, and compared to the five
store-bought mushrooms and organic brown rice. Unlike UV and
MS, an ELSD system is a mass-dependent detector, thus it does not
depend on spectral or physicochemical properties of the analytes
(Eom et al., 2010; Vehovec and Obreza, 2010). Because the ELSD is
mass dependent, the size of peaks is directly correlated to the mass
of constituents within the peak.
The majority of the summed MS signals (abundant m/z peaks in
the mass spectra) corresponding to those ELSD signals contained
matching m/z values (within ±5 ppm) with at least one of theTable 3
Chaga - Contribution of mass spectral features that differ from culinary mushrooms to t
ELSD retention time (min)a HRMS retention time (min)b Area (ELSD)c
6.06 5.96 2.16  107
7.94 7.84 3.50  109
8.00 7.90 5.36  108
8.07 7.97 3.02  108
8.37 8.27 8.75  107
8.62 8.52 1.77  107
8.41 8.31 6.95  108
8.73 8.63 7.20  107
8.81 8.71 4.74  107
8.89 8.79 3.76  107
Total Evaluated:
Total Unevaluated:
(a, b): Retention times [ELSD(a) and HRMS(b)] peaks analyzed. (c, d): Peak area and corre
determined by comparing mass spectral features to culinary mushroom extracts. (f): Thculinary extracts, according to the HRMS data. In other words, the
majority of constituent masses found in each extract were found in
one or more culinary mushroom extracts and/or the brown rice
substrate extract.
3.3.1. Chaga
Over 97% of the total ELSD signal for the Chaga extract, which
accounted for all chromatographic peaks with an area greater than
0.33%, was examined in detail using HRMS (Table 3). A comparison
of base peak mass spectrometry chromatograms and ELSD chro-
matograms was made between the Chaga extract and the extracts
of store-bought Porcini, Crimini, Blank Trumpet, Chanterelle, and
Shiitake mushrooms, as well as an organic brown rice extract
(Fig. 4).
An example of the analysis undertaken can be seen by
comparing the peak at 6.06 min on the ELSD (0.40% of total signal;
Table 3), which correlates to the peak at 5.96 min on the mass
spectrometer (lag related to post-column tubing volumes after
split). The summed mass spectrum at 5.96 min displays several
prominent m/z signals (Fig. 5A). A partial mass spectrum encom-
passing the most intense masses of the organic Chaga extract was
compared to the MS spectra of the extracts for the culinary
mushroom samples (Fig. 5B). Exact mass chromatograms for each
of these accurate masses (±5 ppm) were compared to the store-
bought mushroom samples (Fig. 6). As can be seen in this figure,he estimated difference of the raw material from food.
Area %d Peak % differencee Total % difference (peak diff.  area)f
0.4 0 0.0
64.3 0 0.0
9.8 0 0.0
5.6 0 0.0
1.6 0 0.0
0.3 0 0.0
12.8 0 0.0
1.3 0 0.0
0.9 0 0.0
0.7 0 0.0
98. Total Different: 0.0
2.0 Total Similar: 98.
sponding area % of peaks analyzed. (e): Estimated percent difference of that peak as
e percent contribution of these differences to the raw material as a whole.
Fig. 4. Comparison of Chaga ELSD and base peak MS chromatograms to corresponding
culinary mushroom and brown rice chromatograms. (For interpretation of the refer-
ences to colour in this figure legend, the reader is referred to the web version of this
article.)
Fig. 5. Mass spectra at 5.96 min, unzoomed (A) and zoomed to examine prominent m/
z (B).
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5.96 min, matching accurate masses (±5 ppm) were identified in at
least one of the culinary samples. This analysis of accurate mass
chromatograms was performed in an identical manner for each of
the ten ELSD signals that make up 98% of the Chaga extract's mass.
The top HRMS signals correlating to each ELSD signal for the Chaga
powder were all matched to signals found in a store-bought
mushroom or brown rice, and the extract was determined to be
approximately 98% similar to culinary mushrooms, with roughly
2.0% unevaluated due to low signal (Table 3). It is important to note
that there was no attempt to identify the chemical constituents
observed by this process. Rather, the assumption was made that if,
following identical extraction from two fungi, analytes that had the
same observed chromatographic retention time and accurate mass
spectrometry signal, then they were identical for the purposes of
hazard assessment.3.3.2. Reishi
A similar analysis was performed on the Reishi mycelium extract
and Reishi fruiting body extract. The mycelium powder and fruiting
body powder are combined (80% mycelium and 20% fruiting body
by mass) in the final commercial raw material, but the individual
subcomponents were obtained, and chemically analyzed
separately.
Over 95.0% of the ELSD signals were examined by HRMS for both
the mycelium and fruiting body powders (Tables 3 and 4). While
most HRMS signals were matched to signals in a culinary material,
there were several instances that required deeper analysis. For
example, when examining the peak at 8.27 min (Fig. 7B) in the
Reishi mycelium extract, the majority of the signals were matched
in relation to the extracts of the store-bought samples (Fig. 8).
However, there was a signal atm/z 575.3332 (±5 ppm) which could
not bematched to amass spectral feature (m/z and RTcombination)
in any of the culinary extracts (Fig. 9).
This comparisonwas repeated for eachmass spectral peak in the
Reishi mycelium (Fig. 7), and each peak was assigned a percent-
difference. In the example given, the ELSD peak at 8.27 min
Fig. 6. Intensity-normalized exact mass chromatograms of Chaga, store-bought culi-
nary mushrooms, and brown rice extracts at 5.96 min. (For interpretation of the ref-
erences to colour in this figure legend, the reader is referred to the web version of this
article.)
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mately 1/6 of the peaks analyzed, rounded up (Table 4). The peak at
7.84min (Fig. 7A) also had one non-matching HRMS signal, andwas
assigned a 20% difference; the peak at 8.32 min (Fig. 7C) had one
non-matching HRMS signal, which represented a smaller per-
centage of the peaks evaluated, and was assigned a 15% difference.
In all cases, the estimated “difference” was rounded up, in an effort
to more conservatively estimate the similarity to the culinary
samples. After these percent-differences were assigned, they were
thenmultiplied by the area of each peak. Thus, the 20% difference of
the peak at 7.94 min (Fig. 7A) was multiplied by the area of the
peak, 37.51% (Table 4), to give a contribution to the total difference
of 7.5%. Repeating this process for the other two peaks resulted in a
contributed difference of 0.3% for the peak at 8.37 min, and 7.0% for
the peak at 8.32 min. Adding these values together provided a total
estimated difference of 16%. This calculation is made possiblebecause of the mass dependence of the ELSD. In total, the Reishi
mycelium extract was estimated to contain 80% similar material
(compared to the culinary extracts),16% different material, and 4.0%
unevaluated (Table 4).
In the Reishi fruiting body, several analytes were detected that
were unique to the sample and not found in the store-bought
samples (Fig. 10). As with the Reishi mycelium, the exact mass
chromatograms were compared to the store-bought samples, but
there were many unmatched mass spectral features. An example is
shown in Fig. 11. As a result of the numerous unmatched m/z in the
extracted ion chromatograms (XICs), many of the ELSD peaks were
assigned high degrees of percent-difference (Table 5). In total, the
Reishi fruiting body was estimated to contain 58% similar material
(compared to the culinary extracts), 37% different material, and
5.0% unevaluated (Table 5). These evaluations were then combined
to adjust for the 80:20 ratio at which the mycelium and fruiting
body powders are combined in the finished commercial raw ma-
terial. In total, the Reishi raw material extract was estimated to
contain 75% similar constituents, 21% different material, and 4.0%
unevaluated material.
3.3.3. Shiitake, Maitake, Turkey tail
The comparisons to store-bought culinary mushrooms
described above were performed in an identical manner for the
Shiitake, Maitake, and Turkey Tail raw materials. Results are sum-
marized in Tables 6, 7, and 8. All three showed very few differences
from the culinary mushrooms; however, these data served to verify
the general approach. The similarity of the Shiitake and Maitake
raw materials to the culinary mushrooms was not unexpected,
given their use as foods, but the analyses ensured that the myce-
lium were not substantially different from the fruiting bodies used
as food.
3.3.4. Wild-Crafted Chaga and Cordyceps
Because the identity of these fungal raw materials were incor-
rect, as determined by the DNA analysis, neither further charac-
terization work nor hazard assessment were pursued.
3.4. Literature review
As this paper is not meant to be a systematic review of the
literature, results of our literature search are summarized here,
with selected papers referenced. A complete list of references
retrieved may be found in the supplemental information.
3.4.1. Chaga
Inonotus obliquus is found primarily on Birch trees in colder
climates. While it is used in TCM (Zhong et al., 2009), the available
toxicological data are limited. The polysaccharide fraction has been
tested in an acute mouse assay (no mortality at a maximum dose of
5 g/kg body weight) (Haixia et al., 2009). An aqueous extract of the
mycelium has been evaluated in rats for reproductive and devel-
opmental toxicity (neither fetal nor maternal toxicity at 2 mL/kg
i.p.) (Anasiewicz et al., 1998). Ethyl acetate and methanolic extracts
were not mutagenic in an Ames test (TA98 and TA100, up to 50 mg/
plate) (Ham et al., 2009). An undefined extract was reported to not
cause any toxic effects over five to six months in rats or rabbits at
oral doses up to 0.3 g/kg body weight (Shikov et al., 2014) although
the original reference could not be retrieved.
3.4.2. Reishi
This fungus has been used as a medicinal food in China, Japan,
Taiwan, and other Asian regions for centuries (Paterson, 2006).
Known in TCM as ling zhi, the fruiting bodies are used for a number
of ailments, in doses of up to 15 g in decoctions, and up to 3 g in
Table 4
Reishi Mycelium - Contribution of mass spectral features that differ from culinary mushrooms to the estimated difference of the raw material from food.
ELSD retention time (min)a HRMS retention time (min)b Area (ELSD)c Area %d Peak % differencee Total % difference (peak diff.  area)f
7.94 7.84 3.39  109 37.5 20 7.5
8.37 8.27 1.74  108 1.9 20 0.3
8.42 8.32 5.12  109 56.7 15 7.0
Total Evaluated: 96. Total Different: 16.
Total Unevaluated: 4.0 Total Similar: 80.
(a, b): Retention times [ELSD(a) and HRMS(b)] peaks analyzed. (c, d): Peak area and corresponding area % of peaks analyzed. (e): Estimated percent difference of that peak as
determined by comparing mass spectral features to culinary mushroom extracts. (f): The percent contribution of these differences to the raw material as a whole.
Fig. 7. The summed mass spectra at each retention time correlating to a prominent
ELSD signal (>0.33%) with the mis-matching m/z values highlighted in red. (For
interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
Fig. 8. Representative data of the matching intensity-normalized exact mass chro-
matograms for the Reishi mycelium extract with store-bought culinary mushrooms or
brown rice extracts at 8.27 min from Fig. 7B. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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studies were available for Ganoderma lucidum (Reishi) prepara-
tions, including primarily acute and subacute studies. Two 90-day
studies on the polysaccharide fraction (oral route) provided
NOAELs (No Observed Adverse Effect Levels) of 1200 mg/kg/day
(Wihastuti et al., 2014, 2015) and 2000 mg/kg/day (Chen et al.,
2011); these NOAELs were the highest doses used in the studies.
A number of mutagenicity (Ames) tests were available for a variety
of preparations, including aqueous and methanolic extracts of
mycelium, fruiting bodies, and spore powder. Genotoxicity studies
included an in vitro chromosomal aberration assay and in vivo pe-
ripheral blood micronucleus tests of the polysaccharide fraction
(Chen et al., 2011). Nine clinical trials were found in the literature,
all reporting that G. lucidum preparations were well tolerated. One
of these concluded that therewere no negative liver, kidney, or DNA
effects over the 4-week study, as assessed by monitoring the par-
ticipants’ aspartate aminotransferase, alanine transaminase, creat-
inine, and performing a comet assay (Wachtel-Galor et al., 2004).
One of the 90-day studies included gross necropsy and histopa-
thology of reproductive organs (Chen et al., 2011), though other-
wise, traditional developmental and reproductive studies were
lacking. In general, there was no evidence in the literature of any
toxic effects.
3.4.3. Shiitake
The fruiting bodies of Lentinula edodes are a common food,
particularly in Asia. Numerous toxicological studies covering the
common endpoints are available (Supplemental Information).
Perhaps unsurprisingly, minimal toxicity has been seen in systemic
(Yoshioka et al., 2010) and DART (Frizo et al., 2014) studies via the
oral route. Mutagenicity (von Wright et al., 1982) and genotoxicity(de Lima et al., 2001; Miyaji et al., 2006) assays have all reported
negative results. Several clinical trials were found in the literature,
reporting only mild, transient gastrointestinal symptoms (Levy
et al.; Spierings et al., 2007; Yoshioka et al., 2009).
3.4.4. Maitake
Like Shiitake, Maitake is a common food. Conventional toxi-
cology studies are more limited than that found for Shiitake, but
include several subchronic (up to 120 days) studies in mice (oral)
(Kodama et al., 2002; Nanba, 1997) and a chronic (13months) study
Fig. 9. Representative data of a mis-match for the intensity-normalized exact mass
chromatogram of 575.3332 (±5 ppm) in Reishi mycelium against the store-bought
culinary mushrooms and brown rice extracts at 8.27 min from Fig. 7B. This suggests
the presence of an analyte unique to Reishi Mycelium, relative to the store bought
samples. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
Fig. 10. Mass spectra showing high levels of mis-matched m/z comparing the Reishi
fruiting body and culinary extracts at 7.05 min (MS).
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dose. Two in vitro cytotoxicity assays probing embryotoxicity
(mouse embryonic fibroblast (BALB/3T3) cells) and neurotoxicity
(mouse neuroblastoma (N2a) cells) reported no toxicity at the
highest dose) (Phan et al., 2013). Three clinical trials were found
(Deng et al., 2009; Glauco et al., 2004; Wesa et al., 2015), including
two on a hot water-ethanol extract of the fruiting bodies; adverse
events included mild nausea, and a grade I allergic reaction (rash
and pruritus).3.4.5. Turkey tail
There is some discrepancy in mushroom reference books con-
cerning the edibility of Turkey Tail, though it appears that those
that list it as inedible do so because of its fibrous texture and un-
palatability, rather than any known toxicity (Cotter, 2014; Lamaison
and Polese, 2008; Meuninck, 2015; Phillips et al., 2010; Russell,
2006; Spahr, 2009). One of its constituents, Polysaccharide-K, dis-
plays anticancer effects in vitro (Fisher and Yang, 2002), and is being
studied as an adjuvant in the treatment of some cancers. As a result,
some systemic (Hor et al., 2011; Lai et al., 2011), DART (Ng and Chan,
1997), and even clinical studies (Chu et al., 2002; Ito et al., 2004;
Ohwada et al., 2004; Tsang et al., 2003), on the safety of aqueous
extracts and concentrated polysaccharide fractions are available.
Results reported in these studies indicate that the extract is not
embryotoxic, abortifacient, genotoxic, or clastogenic. NOAELs re-
ported for the polysaccharide extract include 1000 mg/kg/day
(mice, oral, 28-day) (Lai et al., 2011) and 5000mg/kg/day (rats, oral,28-day) (Hor et al., 2011); both of these represent the highest dose
tested. Studies on other preparations and extracts are limited
(Knezevic et al., 2015; Torkelson et al., 2012; Zhang et al., 2015).
3.5. In-market data
To gauge in-market presence of each fungal raw material, the
DSLD (Knezevic et al., 2015) was searched for products containing
similar ingredients. The DSLD is maintained by the Office of Dietary
Supplements and the U.S. National Library of Medicine, and con-
tains a comprehensive record of the label information for dietary
supplements in the United States market.
3.5.1. Chaga
The most common Chaga ingredient on labels in the DSLD was
reported as “Chaga” (41 products). Other ingredients, 9 in total,
included variations of “Chaga Extract,” “Chaga Mushroom,” and
“Organic Chaga.” There were, in total, 70 products that reported
some version of “Chaga” on the label; this number is likely inflated,
as some products may include more than one version of the
ingredient. A total of eight distinct brand names were reported.
Some products did not report a dose, instead listing only the dose of
a proprietary blend in which Chaga was included. Others listed the
dose of an extract, but not the equivalence. Of the doses available in
the DSLD, the maximum was 1000 mg, while the median was
120 mg.
3.5.2. Reishi
The most common Reishi ingredients were “Reishi” (109
Fig. 11. Intensity-normalized exact mass chromatograms for 450.32003 (±5 ppm),
showing no match between the Reishi fruiting body peak at RT 7.05 (MS) to any of the
culinary extracts.
Table 5
Reishi Fruiting Body - Contribution of mass spectral features that differ from culinary m
ELSD retention time (min)a HRMS retention time (min)b Area (ELSD)c
6.20 6.10 4.80  107
6.66 6.56 1.02  108
6.71 6.61 1.42  108
6.87 6.77 2.95  108
7.15 7.05 4.97  107
7.35 7.25 9.91  108
7.57 7.47 7.71  107
7.85 7.75 2.93  108
7.96 7.86 1.07  109
8.37 8.27 4.87  107
8.43 8.33 4.28  108
8.65 8.55 1.34  107
8.83 8.73 7.42  107
Total Evaluated:
Total Unevaluated:
(a, b): Retention times [ELSD(a) and HRMS(b)] peaks analyzed. (c, d): Peak area and corre
determined by comparing mass spectral features to culinary mushroom extracts. (f): Th
Table 6
Shiitake - Contribution of mass spectral features that differ from culinary mushrooms to
ELSD retention time (min)a HRMS retention time (min)b Area (ELSD)c
6.87 6.77 4.91  107
7.57 7.47 5.49  107
7.96 7.86 5.52  109
8.38 8.28 3.80  108
8.43 8.33 7.08  109
8.91 8.81 4.19  107
Total Evaluated:
Total Unevaluated:
(a, b): Retention times [ELSD(a) and HRMS(b)] peaks analyzed. (c, d): Peak area and corre
determined by comparing mass spectral features to culinary mushroom extracts. (f): Th
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(24 products). Other ingredients listed included variations of these
ingredient names, as well as variations of “Reishi Extract.” The total
number of products listed was 315; however there a high degree of
overlap, as some products contain more than one “Reishi” ingre-
dient. Within these products, 28 unique brand names were found.
Most products did not report the dose of the ingredient, instead
listing only the dose of a proprietary blend in which Reishi was
included. Of the doses reported, the maximum dose was 4500 mg,
and the median dose was 100 mg.
3.5.3. Shiitake
The most common Shiitake ingredients were “Shiitake” (98
products), and “Shiitake Mushroom” (43 products). A total of 223
products were listed, although some products likely include mul-
tiple versions of the “Shiitake” ingredients. Within the “Shiitake”
and “Shiitake Mushroom” ingredients, 45 distinct brand names
were found. Most products did not report the dose of the ingre-
dient, instead listing only the dose of a proprietary blend in which
Shiitake was included. Of the doses reported, the maximum dose
was 1500 mg, and the median dose was 50 mg.
3.5.4. Maitake
The most common Maitake ingredients were “Maitake” (99
products), and “Maitake Mushroom” (48 products). A total of 267
products containing a Maitake ingredient were listed, although
some products may include multiple versions, thus slightly
inflating this number. Within the “Maitake” and “Maitake Mush-
room” ingredients, 48 distinct brand names were identified. Most
products did not report the dose of the ingredient, instead listing
only the dose of a proprietary blend inwhichMaitakewas included.
Of the doses reported, the maximum dose was 900 mg, and the
median dose was 60 mg.ushrooms to the estimated difference of the raw material from food.
Area %d Peak % differencee Total % difference (peak diff.  area)f
1.3 50 0.6
2.7 100 2.7
3.7 95 3.6
7.8 95 7.4
1.3 100 1.3
26.0 50 13.
2.0 90 1.8
7.7 0 0.0
28.0 0 0.0
1.3 10 0.1
11.2 50 5.6
0.4 25 0.1
2.0 50 1.0
95 Total Different: 37
5.0 Total Similar: 58
sponding area % of peaks analyzed. (e): Estimated percent difference of that peak as
e percent contribution of these differences to the raw material as a whole.
the estimated difference of the raw material from food.
Area %d Peak % differencee Total % difference (peak diff.  area)f
0.4 0 0.0
0.4 0 0.0
41.2 0 0.0
2.8 0 0.0
52.9 0 0.0
0.3 0 0.0
98 Total Different: 0.0
2.0 Total Similar: 98
sponding area % of peaks analyzed. (e): Estimated percent difference of that peak as
e percent contribution of these differences to the raw material as a whole.
Table 7
Maitake - Contribution of mass spectral features that differ from culinary mushrooms to the estimated difference of the raw material from food.
ELSD retention time (min)a HRMS retention time (min)b Area (ELSD)c Area %d Peak % differencee Total % difference (peak diff.  area)f
7.96 7.86 1.02  1010 38.7 0 0.0
8.36 8.26 9.10  108 3.5 25 0.9
8.46 8.36 1.46  1010 55.6 0 0.00
8.84 8.74 1.30  108 0.5 50 0.3
8.9 8.8 1.36  108 0.5 0 0.00
Total Evaluated: 99 Total Different: 1.0
Total Unevaluated: 1.0 Total Similar: 98
(a, b): Retention times [ELSD(a) and HRMS(b)] peaks analyzed. (c, d): Peak area and corresponding area % of peaks analyzed. (e): Estimated percent difference of that peak as
determined by comparing mass spectral features to culinary mushroom extracts. (f): The percent contribution of these differences to the raw material as a whole.
Table 8
Turkey Tail - Contribution of mass spectral features that differ from culinary mushrooms to the estimated difference of the raw material from food.
ELSD retention time (min)a HRMS retention time (min)b Area (ELSD)c Area %d Peak % differencee Total % difference (peak diff.  area)f
7.83 7.76 453  106 28.2 0 0.00
8.25 8.18 200  106 12.5 0 0.00
8.32 8.25 716  106 44.6 0 0.00
8.76 8.69 532  104 0.3 0 0.00
8.86 8.79 346  105 2.2 25 0.5
8.99 8.92 213  105 1.3 0 0.00
9.19 9.12 120  106 7.5 0 0.00
9.36 9.29 106  104 0.7 50 0.3
9.68 9.61 551  104 0.3 0 0.00
9.96 9.89 178  105 1.1 0 0.00
Total Evaluated: 99 Total Different: 1.0
Total Unevaluated: 1.0 Total Similar: 98
(a, b): Retention times [ELSD(a) and HRMS(b)] peaks analyzed. (c, d): Peak area and corresponding area % of peaks analyzed. (e): Estimated percent difference of that peak as
determined by comparing mass spectral features to culinary mushroom extracts. (f): The percent contribution of these differences to the raw material as a whole.
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The most common Turkey Tail ingredient was listed as “Turkey
Tails,” and included only 17 products; the total number of products
containing some type of Turkey Tail ingredient was 39. Including all
reported Turkey Tail ingredients, 12 distinct brands were identified.
The highest reported dose of Turkey tail was 1 g, and themedian (of
11 reported doses) was 120 mg.4. Discussion
In the absence of comprehensive toxicological studies, a weight
of evidence approachmust be takenwhen evaluating rawmaterials
for safe inclusion in dietary supplements. Of primary importance is
a positive identification of the fungal raw material. The difficulty of
relying solely on macro- or microscopic techniques was demon-
strated when two of the eight fungal raw materials under investi-
gation proved to be misidentified (Raja et al., 2017).
The dereplication results provided a targeted approach for the
safety assessment of the fungal rawmaterials, in that known fungal
metabolites and mycotoxins were screened for directly. Ergosterol
peroxide was detected in all of the fungi, including the store-
bought culinary mushrooms. Ergosterol peroxide had been previ-
ously reported to be found in edible mushrooms (it is a sterol found
in the cell membranes of all fungi), and therefore was not consid-
ered a harmful component from any of the mushrooms at dietary
intake levels (Kobori et al., 2007; Krzyczkowski et al., 2009). While
the Shiitake mycelium raw material (but not the store-bought
fruiting body) also contained pyrenocine A and pughiinin A,
neither of these compounds have reported toxic effects except to
plants. Furthermore, neither were found in considerable quantities
based on the ELSD signals (<0.10% of the total ELSD signal), indi-
cating that their levels could be controlled by adjusting the dose of
the raw materials. No known mycotoxins were detected in any of
the raw materials.The confirmation of identity and dereplication steps represent a
screening stage in the overall process of assessing the safety of
fungal rawmaterials. They are necessary, but very binary, steps that
must be taken to ensure that the material purchased is the same
being evaluated. Amisidentified rawmaterial cannot be safely used
in a product; likewise, detection of any known mycotoxins imme-
diately requires further risk assessment. Chemically comparing the
fungal raw materials to culinary mushrooms represents a much
more nuanced perspective that depends on an accepted safe
exposure to dietary ingredients in a genetically diverse and
significantly broad population. “Different” metabolites do not
necessarily represent harm, but a lack of toxicological literature on
that material could elevate the risk of using a material with a
metabolomic profile different from food mushrooms. The purpose
of comparing the fungal raw materials to foods on a constituent
level was to more completely characterize and quantify this risk.
Where insufficient literature is available, these now-quantified
differences could be controlled and minimized by adjusting dose
in the final product.
The chemical comparison of the MS peaks was both very
defined and somewhat subjective. Matching retention time, accu-
rate mass, and contribution to peak area (i.e., by matching the size
and shape of chromatographic peaks) is an accepted and reliable
way confirm that two unknown constituents are the same (El-
Elimat et al., 2013). In other words, it was reasonable to assume
identical molecular species were present in two samples when the
retention and accurate mass signals were identical. The identity of
the analytewas not considered to be crucial, only its presence in the
commonly consumed culinary mushrooms. While unique compo-
nents could be analyzed further, to inform decision-making or
refine dose, such analyses were not within the scope of this study.
In contrast, choosing a cutoff threshold for which MS peaks to
compare proved challenging. For some samples, it was clearly
evident which m/z signals contributed to the ELSD signal based on
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matogram peaks to ELSD peaks, thus only thosem/zwere analyzed
(Fig. 7A). For spectra that were less clear, the top six most intense
peaks were selected (Fig. 7B). However, in rare instances, the lower
abundant signals of the top six peaks were too similar in intensity
to determine which were significant, thus up to eight peaks were
selected and analyzed further (Fig. 7C). While this selection process
was flexible in terms of numbers of m/z peaks considered, it pro-
vided a more thorough analysis then selecting a set number of
peaks and ignoring signals similar in intensity.
Assessing the safety of the fungal raw materials requires expert
knowledge and judgement. Strong evidence of safe human use
would theoretically consist of positive DNA identification, no
detected mycotoxins, a very high degree of similarity to culinary
mushrooms, thorough information in the literature on the chem-
istry and safety of the material, and/or broad market prevalence.
Weak evidence of safety could result from data gaps in the litera-
ture, significant degrees of difference from culinary mushrooms,
and/or limited market presence. Major data gaps in the literature, a
high degree of difference from the analyzed culinary mushrooms
on a constituent-level basis, and/or little or no documented market
presence would suggest inadequate evidence of safety and more
traditional toxicological studies would be required. Further
analytical investigations focused on differences would in such cases
yield a better understanding of the constituent profile and helpTable 9
Weight-of-evidence summary for evaluated raw materials.
Raw material Identity verified
by DNA
Dereplication Similarity to grocery
store mushrooms
Preva
mark
Chaga Yes No toxins detected 98% similar
2% unevaluated
70 pr
media
Reishi (Mycelium þ
Fruiting Bodies)
Yes No toxins detected 75% similar
21% “different”
4% unevaluated
315 p
media
Shiitake Yes No toxins detected 98% similar
2% unevaluated
223 p
media
Maitake Yes No toxins detected 98% similar
1% “different”
1% unevaluated
267 p
media
Turkey Tail Yes No toxins detected 98% similar
1% “different”
1% unevaluated
39 pr
media
Wild Chaga No ———————————————————————————
———————————————————————————
Cordyceps No ———————————————————————————
———————————————————————————inform design of further studies. An incorrectly identified fungal
raw material, detection of a mycotoxin, known serious adverse
events associated with the fungus in the marketplace, and/or in-
dications of toxicity in the safety literature would indicate that the
safe use of that fungal rawmaterial could not be supported without
out further investigation.
A summary of the weight-of-evidence approach used for the
raw materials in this study can be found in Table 9.
While evaluating the fungal raw materials, the most straight-
forward were those that are often considered food, and/or had a
high degree of similarity to the culinary materials. For example,
both Shiitake and Maitake are commonly eaten as foods, and
Shiitake, at least, has a wealth of available toxicological data sup-
porting its safe use. The apparent prevalence in the marketplace,
the lack of reported adverse events, as determined by the literature
review and the very high degree of similarity between their
mycelium growths (the raw materials investigated) and the culi-
nary fruiting bodies to which they were compared give confidence
that these materials are safe for consumption at doses consistent
with dietary intakes of culinary mushrooms.
The literature search results were much more limited for Turkey
Tail and Chaga, necessitating a heavier reliance on other data.While
there were no indications of toxicity, particularly for aqueous ex-
tracts of the two mushrooms, conventional toxicological data were
not available for most endpoints and non-aqueous preparations.lence in the
et
Published literature Weight of evidence evaluation
oducts,
n dose 120 mg
Limited toxicological data. No
reported toxic effects.
Chemically very similar to food.
Likely poses no greater risk
than culinary mushrooms,
particularly if unevaluated
portion is minimized through
dose.
roducts,
n dose 100 mg
Long history of use as medicinal
food in Asian countries.
Subchronic and acute studies
available. Nine clinical trials,
one of which monitored safety
endpoints. Traditional
developmental and
reproductive studies lacking.
Limited genotoxicity data
available. No evidence of toxic
effects.
Not a high similarity to culinary
mushrooms; necessitates
greater reliance on substantial
history of use and available
toxicological data.
roducts,
n dose 50 mg
Long history of use as food
(fruiting body). Numerous
toxicological studies available,
showing minimal toxicity.
Chemically very similar to food.
Existing history of use and
available toxicological data
indicate no greater risk than
culinary mushrooms.
roducts,
n dose 60 mg
Long history of use as food
(fruiting body). Subchronic oral
studies available. Limited data
on other endpoints in literature.
Chemically very similar to food.
Likely poses no greater risk
than culinary mushrooms,
particularly if “different”/
unevaluated portion is
minimized through dose.
oducts,
n dose 120 mg
Aqueous extracts heavily
studied, results indicating no
apparent toxicity. Studies on
other extracts are limited.
Chemically very similar to food.
Some toxicological data
available. Likely poses no
greater risk than culinary
mushrooms, particularly if
“different”/unevaluated portion
is minimized through dose.
———— assessment not continued
————
Weight of evidence evaluation
not possible without positive
identification.
———— assessment not continued
————
Weight of evidence evaluation
not possible without positive
identification.
K.M. VanderMolen et al. / Food and Chemical Toxicology 103 (2017) 133e147146Chaga ingredients were more prevalent in the marketplace than
some of the othermaterials assessed (up to 70 products, as opposed
to 39 listed for Turkey Tail), but not as prevalent as Reishi (up to 315
products). In general, fungal ingredients appear not to be particu-
larly popular in the market; searches of the DSLD for “Ginger” and
“Turmeric” for instance provided hits for up to 1660 products and
1082 products, respectively. However, Chaga does appear in the
marketplace at relatively high doses (up to 1000 mg), and there
were no data found in the literature that indicated associated
adverse events. Combined with the fact that there were no
detectable differences from the culinary ingredients, it was deter-
mined that further workwas not necessary to support its safe use at
doses consistent with those currently in the marketplace. Likewise,
the Turkey Tail had a very high degree of similarity to the culinary
ingredients, and certain preparations are being studied in humans,
with no apparent toxic effects (Chu et al., 2002; Ito et al., 2004;
Ohwada et al., 2004; Tsang et al., 2003). While it does not appear
to have as large a market presence as the other fungal ingredients
studied, it is, in general, considered edible (Cotter, 2014; Russell,
2006; Spahr, 2009) though unpalatable. Based on the available
weight of evidence, its safe use can likely be supported without
further studies, especially if the dissimilarity from culinary in-
gredients is minimized by using a smaller dose.
The Reishi rawmaterial was the most different, when compared
to the culinary ingredients, but there was substantially more liter-
ature (Bensky et al., 2004; Chen et al., 2011; Wachtel-Galor et al.,
2004; Wihastuti et al., 2014, 2015) to support its safe use in sup-
plements (see Supplemental Information for the complete list of
references evaluated). It appeared to have the broadest market
presence of any of the fungalmaterials studied (up to 315 products),
with a number of different preparations available to consumers. It is
reasonable that the long history of use, presence in the market-
place, and abundant toxicological literature outweighs the
dissimilarity from common food mushrooms.
Evaluating complex mixtures for human safety, particularly one
that could vary from lot-to-lot, presents a number of challenges.
Maintaining consistent methods of production and preparation
becomes critical to yielding a similar product. While known toxins
can theoretically be screened for through dereplication (El-Elimat
et al., 2013), this requires a thorough and maintained database of
constituents to compare against. Importantly, it does not include
unknown toxins, necessitating further steps to ensure safe con-
sumption. Likewise, chemical comparison to food can provide ev-
idence of safety if there is a very high degree of similarity, but
dissimilarity does not necessarily indicate toxicity. Toxicological
literature for botanicals and traditional medicines can be sparse,
and often not directly address the preparation of interest; this
challenge is probably even greater for those based on fungal
preparations, due to the differences in growing conditions between
traditionally used materials and commercially available in-
gredients. Using a weight of evidence approach, including existing
literature, analytical, and in silico tools, provides an alternative
approach to safety assessment, minimizing or even eliminating the
need for animal testing in making decisions for safe human use.
5. Conclusions
The use of the integrated approach and particularly chemical
constituent comparison to common food mushrooms provides a
novel approach to addressing the safety of fungal raw materials. In
the absence of the usual suite of toxicological studies, a comparison
to common food can be made, with the ultimate conclusion being
that the materials with high degrees of similarity are nomore a risk
to the consumer than that of food. Components may be identified
either in the dereplication step or the chemical comparison stepthat require further evaluation, but the systematic approach of
comparing the chemical profiles to that of something inherently
low-risk (food) allows these constituents to be prioritized. In many
cases, as with ergosterol peroxide, these components can be
excluded using solely literature resources.
It is important to note that this method of evaluation is specific
to the particular cultivation of the fungi and the dose evaluated.
Constituents in the fungal raw material that differ from available
culinary mushrooms may be restricted to safe levels by adjusting
dose. Changing the cultivation process of the fungus can change the
secondary metabolome profile, thus changing the levels of any
constituents of concern. This would necessitate a reevaluation of
raw material to ensure that any new metabolites are considered
and restricted to safe levels if appropriate. However, these same
limitations apply to a more traditional suite of toxicological tests; a
change in the raw material raises questions as to whether the
studies sufficiently address the safety of the new material.
Incorporating analytical and in silico tools to the safety assess-
ment of natural materials offers a number of tangible benefits. In
addition to cost and time savings, there is a reduced demand on the
number of animals required to ensure the safe human use of the
material. Both initial evaluations and comparisons to new or similar
materials can be performed in an expedited and less resource
intensive fashion.
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